You are here: Industry Insights > FDA

News List

US needs to look differently at public health preparedness, says former FDA commissioner Gottlieb cphi-online
July 29, 2021
Speaking at CPhI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities
FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes fda.gov
July 29, 2021
Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
Regulators call for clinical research to include pregnant and breastfeeding women europeanpharmaceuticalreview
July 28, 2021
The FDA and other global regulators are co-operating to address inadequacies in clinical research that leave pregnant and breastfeeding women lacking data on which to base their medical decisions.
US FDA approves Shingrix to prevent shingles in immuno-compromised adults expresspharma
July 28, 2021
Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine, given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older.
FDA Accepts Braeburn’s New Drug Application Resubmission for Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder drugs
July 28, 2021
Braeburn announces that the New Drug Application (NDA) for Brixadi (buprenorphine) extended-release weekly and monthly injection for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the FDA.
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem drugs
July 28, 2021
Iterum Therapeutics plc (Nasdaq: ITRM) today announced that it received a Complete Response Letter (CRL) from the FDA for its NDA for sulopenem etzadroxil/probenecid (oral sulopenem) on July 23, 2021.
FDA Approves Twyneo (tretinoin and benzoyl peroxide) for the Treatment of Acne Vulgaris drugs
July 28, 2021
Sol-Gel Technologies, Ltd. today announced that FDA has approved its first proprietary drug product, Twyneo cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
Sol-Gel Technologies Announces FDA Approval of TWYNEO firstwordpharma
July 28, 2021
Sol-GSol-Gel Technologies approved its first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years.
Shingrix Approved for Shingles Prevention in Immunocompromised Adults americanpharmaceuticalreview
July 27, 2021
GlaxoSmithKline plc announced that the US FDA has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to ...
Sun Pharma and Cassiopea SpA sign license and supply agreements for Winlevi expresspharma
July 27, 2021
Sun Pharmaceuticals and Cassiopea SpA have signed licence and supply agreements for Winlevi (clascoterone cream 1%) in the United States (US) and Canada.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 365 366 Next page